Turnstone Biologics Corp. reported developments for a biotechnology company historically focused on Selected tumor-infiltrating lymphocyte therapy for solid tumors. Company news covered TIDAL-01 clinical and preclinical data, presentations at Society for Immunotherapy of Cancer meetings, quarterly financial results, pipeline prioritization, cost-containment measures, workforce restructuring, and Nasdaq listing matters.
Turnstone later discontinued TIDAL-01 clinical studies and halted further program development while reviewing strategic alternatives. Subsequent corporate-status disclosures documented an acquisition-related transition, Nasdaq delisting, and termination of Exchange Act registration for its common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.